These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 17130431)

  • 1. Blockade of chemokine signaling in patients with multiple sclerosis.
    Zipp F; Hartung HP; Hillert J; Schimrigk S; Trebst C; Stangel M; Infante-Duarte C; Jakobs P; Wolf C; Sandbrink R; Pohl C; Filippi M;
    Neurology; 2006 Nov; 67(10):1880-3. PubMed ID: 17130431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.
    Polman C; Barkhof F; Sandberg-Wollheim M; Linde A; Nordle O; Nederman T;
    Neurology; 2005 Mar; 64(6):987-91. PubMed ID: 15781813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
    Fazekas F; Lublin FD; Li D; Freedman MS; Hartung HP; Rieckmann P; Sørensen PS; Maas-Enriquez M; Sommerauer B; Hanna K; ;
    Neurology; 2008 Jul; 71(4):265-71. PubMed ID: 18645164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No significant effect of orally administered chemokine receptor 1 antagonist on intercellular adhesion molecule-3 expression in relapsing--remitting multiple sclerosis patients.
    Reuss R; Schreiber V; Klein A; Infante-Duarte C; Filippi M; Pabst W; Pohl C; Oschmann P
    Mult Scler; 2010 Mar; 16(3):366-9. PubMed ID: 20086017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
    Cadavid D; Wolansky LJ; Skurnick J; Lincoln J; Cheriyan J; Szczepanowski K; Kamin SS; Pachner AR; Halper J; Cook SD
    Neurology; 2009 Jun; 72(23):1976-83. PubMed ID: 19279320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial.
    Krapf H; Morrissey SP; Zenker O; Zwingers T; Gonsette R; Hartung HP;
    Neurology; 2005 Sep; 65(5):690-5. PubMed ID: 16157900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemokine receptor CCR1: a new target for progressive kidney disease.
    Ninichuk V; Anders HJ
    Am J Nephrol; 2005; 25(4):365-72. PubMed ID: 16088077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Blockade of chemokines in chronic inflammatory diseases].
    Haringman JJ; Tak PP
    Ned Tijdschr Geneeskd; 2004 Sep; 148(36):1760-4. PubMed ID: 15495938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of experimental autoimmune encephalomyelitis with the chemokine receptor antagonist Met-RANTES.
    Matsui M; Weaver J; Proudfoot AE; Wujek JR; Wei T; Richer E; Trapp BD; Rao A; Ransohoff RM
    J Neuroimmunol; 2002 Jul; 128(1-2):16-22. PubMed ID: 12098506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
    Havrdova E; Zivadinov R; Krasensky J; Dwyer MG; Novakova I; Dolezal O; Ticha V; Dusek L; Houzvickova E; Cox JL; Bergsland N; Hussein S; Svobodnik A; Seidl Z; Vaneckova M; Horakova D
    Mult Scler; 2009 Aug; 15(8):965-76. PubMed ID: 19465443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.
    Rose JW; Burns JB; Bjorklund J; Klein J; Watt HE; Carlson NG
    Neurology; 2007 Aug; 69(8):785-9. PubMed ID: 17709711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A composite score to predict short-term disease activity in patients with relapsing-remitting MS.
    Sormani MP; Rovaris M; Comi G; Filippi M
    Neurology; 2007 Sep; 69(12):1230-5. PubMed ID: 17875911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is natalizumab overshooting its rebound?
    Fox RJ; Kappos L
    Neurology; 2008 Mar; 70(13 Pt 2):1073-4. PubMed ID: 18362270
    [No Abstract]   [Full Text] [Related]  

  • 15. Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.
    Cohen JA; Rovaris M; Goodman AD; Ladkani D; Wynn D; Filippi M;
    Neurology; 2007 Mar; 68(12):939-44. PubMed ID: 17372130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis.
    Cepok S; Schreiber H; Hoffmann S; Zhou D; Neuhaus O; von Geldern G; Hochgesand S; Nessler S; Rothhammer V; Lang M; Hartung HP; Hemmer B
    Arch Neurol; 2009 Oct; 66(10):1216-23. PubMed ID: 19667211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BX-471 Berlex.
    Elices MJ
    Curr Opin Investig Drugs; 2002 Jun; 3(6):865-9. PubMed ID: 12137405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial.
    Bar-Or A; Vollmer T; Antel J; Arnold DL; Bodner CA; Campagnolo D; Gianettoni J; Jalili F; Kachuck N; Lapierre Y; Niino M; Oger J; Price M; Rhodes S; Robinson WH; Shi FD; Utz PJ; Valone F; Weiner L; Steinman L; Garren H
    Arch Neurol; 2007 Oct; 64(10):1407-15. PubMed ID: 17698695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial.
    Rovaris M; Comi G; Rocca MA; Valsasina P; Ladkani D; Pieri E; Weiss S; Shifroni G; Wolinsky JS; Filippi M;
    Mult Scler; 2007 May; 13(4):502-8. PubMed ID: 17483532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serial blood T cell repertoire alterations in multiple sclerosis patients; correlation with clinical and MRI parameters.
    Laplaud DA; Berthelot L; Miqueu P; Bourcier K; Moynard J; Oudinet Y; Guillet M; Ruiz C; Oden N; Brouard S; Guttmann CR; Weiner HL; Khoury SJ; Soulillou JP
    J Neuroimmunol; 2006 Aug; 177(1-2):151-60. PubMed ID: 16806500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.